Sex Differences in 3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy)-Induced Cytochrome P450 2D6 Inhibition in Humans
Authors:
- Brian OʼmahonyBOBrian Oʼmahony
- Clara Pérez-MañáCPClara Pérez-Mañá
- Marcel·lí CarbóMCMarcel·lí Carbó
- Rafael de la TorreRTRafael de la Torre
- 1 May 2011
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 50 (5) , 319-329
Abstract
Background and Objective: 3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is a ring-substituted amphetamine widely used for recreational purposes. MDMA is predominantly O-demethylenated in humans...Keywords
This publication has 59 references indexed in Scilit:
- GENETIC STUDY: 5‐HTTLPR polymorphism, mood disorders and MDMA use in a 3‐year follow‐up studyAddiction Biology, 2009
- Neural and Cardiac Toxicities Associated With 3,4-Methylenedioxymethamphetamine (MDMA)International Review of Neurobiology, 2009
- Effects of Dose and Route of Administration on Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine in the RatDrug Metabolism and Disposition, 2009
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Neurotoxic Thioether Adducts of 3,4-Methylenedioxymethamphetamine Identified in Human Urine After Ecstasy IngestionDrug Metabolism and Disposition, 2009
- Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neuronsPharmacology Biochemistry and Behavior, 2008
- Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine After Controlled Oral Administration to Young AdultsTherapeutic Drug Monitoring, 2008
- Contribution ???of ???Cytochrome??? P450??2D6??to??3,4-Methylenedioxymethamphetamine Disposition in HumansClinical Pharmacokinetics, 2005
- Clinical Pharmacokinetics of Amfetamine and Related SubstancesClinical Pharmacokinetics, 2004
- The Influence of Sex on PharmacokineticsClinical Pharmacokinetics, 2003